GlassScriptPhysician profile
Ivan N Trinh
NPI 1770917940
$4,373.59
in general payments reported to CMS, 2019-2025
24 companies · $457 in 2025
The $457 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,044 · 2022: $30.39 · 2023: $392 · 2024: $451 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,043.97 | 2019 | |
| Astellas Pharma US INC | $136.58 | 2023-2025 | Veozah |
| Alexion Pharmaceuticals, INC. | $132.54 | 2024 | Strensiq |
| Organon LLC | $126.23 | 2023-2025 | Nexplanon |
| Amgen INC. | $123.65 | 2023-2024 | Prolia, Evenity, Repatha |
| Sumitomo Pharma America, INC. | $122.47 | 2023-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $103.89 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $83.95 | 2025 | |
| Exeltis, USA INC. | $76.88 | 2023-2024 | Slynd |
| Glaxosmithkline, LLC. | $49.70 | 2023-2024 | Shingrix, Arexvy |
| Octapharma USA, INC. | $48.09 | 2025 | Fibryga |
| Novo Nordisk INC | $43.13 | 2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $40.66 | 2023-2024 | Vraylar |
| Xeris Pharmaceuticals, INC. | $39.58 | 2023-2024 | Gvoke Hypopen |
| Pfizer INC. | $32.68 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $32.47 | 2023-2025 | Novasure, Acessa Provu System |
| Supernus Pharmaceuticals, INC. | $20.25 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $20.25 | 2025 | Zurzuvae |
| Urovant Sciences INC | $18.00 | 2022 | |
| Exact Sciences Corporation | $17.65 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $17.37 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $14.90 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2025 | Zoryve |
| Minerva Surgical, INC | $14.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Trinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.